Phase 3 Obesity Trial, Recruiting NCT07332273 Sponsor: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud Condition: Obesity
Back to Obesity

Phase 3 Obesity Trial, Recruiting

NCT07332273
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 25 and 60 years of age
  • People with a body mass index (BMI) between 30.0 and 39.9, which falls into the obesity grade I–II range
  • People who have either mildly underactive thyroid function (with a specific hormone level called TSH between 5 and 10, but other thyroid levels normal), or a thyroid that is considered normal but with TSH in the upper range of normal and no known thyroid condition
  • People who are able and willing to sign a consent form agreeing to take part
  • Women who could become pregnant may be eligible if they are not currently pregnant or breastfeeding, and are using a highly effective form of contraception (such as hormonal methods, an IUD, sterilisation, or a combination of two barrier methods with spermicide)

Who may not be able to join:

  • People with diabetes, based on specific blood sugar test results (confirm with trial site for exact values)
  • People who have ever had a thyroid condition such as an overactive or fully underactive thyroid, or who have previously been treated with a thyroid hormone medication called levothyroxine
  • People who have used levothyroxine, blood sugar-lowering medications, antibiotics, or regular probiotic or prebiotic supplements in the past 3 months or are currently using them
  • People who have had cancer in the past 5 years, except for a common and easily treated skin cancer called basal-cell carcinoma
  • People with chronic liver disease with certain elevated liver or bilirubin test results (confirm with trial site for exact values)
  • People with established heart or blood vessel disease, such as a history of stroke, heart disease, or poor circulation in the legs
  • People with a history of an irregular heartbeat, including atrial fibrillation
  • People with high blood pressure above 160/100 mmHg that is not controlled despite treatment, as measured by a blood pressure monitoring test at the screening visit
  • People with any form of heart failure, a resting heart rate above 85 beats per minute, or reduced kidney function below a certain level (confirm with trial site)
  • People known to have HIV, hepatitis B, or hepatitis C infection
  • People with an active inflammatory condition or inflammatory bowel disease
  • People with a serious underlying health condition that, in the opinion of the trial doctor, could affect their ability to participate
  • People with drug or alcohol misuse issues, a life expectancy of less than 12 months, or those who are unable to follow the recommended diet or attend study visits
  • People who are pregnant, have a positive pregnancy test, are planning to become pregnant, or are breastfeeding
  • People with a known allergy or sensitivity to any ingredient in the study treatment
  • People who are unable or unwilling to provide informed consent

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Registry
ClinicalTrials.gov
Start date
5 November 2025
Est. completion
1 November 2026

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

Change in body weight (kg) from baseline to Month 3; Change in fat mass (kg) by bioimpedance from baseline to Month 3

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov